500 patients67,039 observations150 daysLIVE

Patient P-03279

Synthetic patientONX-7 · Day 94 · 25–34 · M · baseline S14Open companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S14
  2. Day 58 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 61 GI-04 recommendedGI Support Protocol GI-04
  4. Day 62 Patient acceptedStarted GI-04 in the companion
  5. Day 70 GI symptom burden −34% vs expectedGI Support Protocol GI-04
  6. Day 76 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 58.

Primary contributors, last 14 days
  • Treatment adherence-25
  • Toxicity+9
  • Inflammatory activity+2

What helped?

  • GI Support Protocol GI-04Day 61
    Result: symptom burden −34%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
62%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 90% showed improvement
  • median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 42
  • Autonomic recovery 45
    • WearableResting HR 80 bpm
    • WearableShort sleep window
  • Mucosal barrier integrity 40
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • WearableSleep 5.7 h, below personal baseline
  • Butyrate / short-chain fatty acid production 25
    • MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 1.9 · butyrate capacity 46/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
60 ms
Sleep
6.5 h
Steps
4,916
Resting HR
77 bpm
Daily log: GI score 42, nutritional resilience 53, adherence 62.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0328946%S03SC-12improved54
P-0304639%S20GI-04no change53
P-0312339%S14GI-04improved50
P-0314638%S14GI-04improved53
P-0310337%S14GI-04improved63
P-0311037%S15GI-04improved52
P-0346537%S17CR-01improved65
P-0307036%S14GI-04improved51
P-0335736%S02CR-01improved50
P-0320135%S15GI-04improved68
P-0330035%S14GI-04improved46
P-0336533%S14NP-02improved46